CSF2 and melanoma: Moreover, the engineered OVs—talimogene laherparepvec—was approved by the FDA in 2015 as the first OV drug for the treatment of melanoma, which is an HSV-1 inserted into the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene toward enhancing the recruitment and activation of DCs.